OCT 18, 2017 08:00 AM PDT

WEBINAR: Vitamin D Measurements: Facts We May Not (Want to) Know

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Medical Director, Informatics and POCT Associate Medical Director, Clinical Chemistry Department of Pathology and Laboratory Medicine Tufts Medical Center
      Dr. Horowitz received his bachelor's degree in chemistry from Harvard College in 1972 and his medical degree from Harvard Medical School in 1976. He completed a clinical pathology residency at Beth Israel Hospital in Boston in 1981, after which he became the Director of Clinical Chemistry at that institution. In 1996, following the merger with New England Deaconess Hospital, he became the Director of Clinical Chemistry for the merged institution, Beth Israel Deaconess Medical Center. In 2017, he transferred to the Department of Pathology and Laboratory Medicine at Tufts Medical Center as the Director of Informatics and Point of Care Testing as well as Visiting Associate Professor of Pathology and Laboratory Medicine at Tufts University School of Medicine.
      He served on the Chemistry Resource Committee of the College of American Pathologists from 2002 through 2010; he was Chair of that committee from 2007 through 2010. He was re-appointed Chair of that committee in 2012 and served in that role through 2016. He has been an active member of the CAP Accuracy-Based Committee since its inception several years ago, and he is currently its Vice Chair.
      Dr. Horowitz has also worked with the Clinical Laboratory Standards Institute (CLSI): he was Chair of the working group on Document C28 (Reference Intervals) and is now Vice-Chair of the working group on Document GP27 (Using Proficiency Testing to Improve the Clinical Laboratory).
      His professional interests include informatics, automation, cardiac markers, therapeutic drug monitoring, and toxicology.
    • Global Director, Product Marketing, Sciex Clinical
        Karla Gonye is the Business unit lead for the Sciex Clinical division, responsible for new product launches including SCIEX mass spectrometers, clinical assays, and mass spec accessories for the global business with a focus on the Americas, Europe, China and APAC. She is based in Framingham Massachusetts and will be introducing our speaker today.


      DATE: October 18, 2017
      TIME: 8:00 AM PST, 11:00 AM EST

      Over the past decade, 25-OH vitamin D has become one of the most common assays requested by physicians.The increase in testing volume has been driven by risk-association studies linking vitamin D not only to calcium homeostasis, but also to cardiovascular disease, stroke, cancer, autoimmune disease, and even fractures.Two major types of assays are used to measure vitamin D – immunoassay and mass spectrometry.  Each of them has its strengths and weaknesses. Measurement is complicated by the existence of two forms of vitamin D (D2 and D3) as well as by the existence of epimers of both forms.  Standardization has only recently been introduced, and proficiency testing, though available, reflects the poor state of the art.  In this session, we will delve into the details of vitamin D measurement, aided by results from a recent study using the first FDA-cleared via the de novo pathway 25-OH vitamin D assay for mass spectrometry. We will discuss ways of acknowledging, and dealing with, limitations of the various assays.

      Learning Objectives:

      • Understand the need for accuracy in testing total 25-OH-vitamin D
      • Evaluate the performance of immunoassay and LC-MS/MS methods for 25-OH vitamin D
      • Recognize the importance of standardization efforts in vitamin D
      • Identify the challenges of external quality control surveys face in testing accuracy

      Show Resources
      Loading Comments...